A practical reference on blood-brain barrier: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-30. Anything still debated is marked as such rather than presented as settled.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Calculated for the free peptide |
| Molecular weight | About 751.9 g/mol | Derived from the sequence |
| Appearance | White to off-white powder | Typical lyophilised form |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
== Ribose 5-phosphates: histidine == In E. coli, the biosynthesis begins with phosphorylation of 5-phosphoribosyl-pyrophosphate (PRPP), catalyzed by ATP-phosphoribosyl transferase. Phosphoribosyl-ATP converts to phosphoribosyl-AMP (PRAMP). His4 then catalyzes the formation of phosphoribosylformiminoAICAR-phosphate, which is then converted to phosphoribulosylformimino-AICAR-P by the His6 gene product. His7 splits phosphoribulosylformimino-AICAR-P to form D-erythro-imidazole-glycerol-phosphate. After, His3 forms imidazole acetol-phosphate releasing water. His5 then makes L-histidinol-phosphate, which is then hydrolyzed by His2 making histidinol. His4 catalyzes the oxidation of L-histidinol to form L-histidinal, an amino aldehyde. In the last step, L-histidinal is converted to L-histidine.
This relation has the correct behavior at extreme values of R∗, as shown by the labeled curve in Figure 3: when R∗ is small, it is consistent with smooth pipe flow, when large, it is consistent with rough pipe flow. However its performance in the transitional domain overestimates the friction factor by a substantial margin. Colebrook acknowledges the discrepancy with Nikuradze's data but argues that his relation is consistent with the measurements on commercial pipes. Indeed, such pipes are very different from those carefully prepared by Nikuradse: their surfaces are characterized by many different roughness heights and random spatial distribution of roughness points, while those of Nikuradse have surfaces with uniform roughness height, with the points extremely closely packed.
The unit cell of these phases has double Bi–O planes which are stacked in a way that the Bi atom of one plane sits below the oxygen atom of the next consecutive plane. The Ca atom forms a layer within the interior of the CuO2 layers in both Bi-2212 and Bi-2223; there is no Ca layer in the Bi-2201 phase. The three phases differ with each other in the number of cuprate planes; Bi-2201, Bi-2212 and Bi-2223 phases have one, two and three CuO2 planes, respectively. The c axis lattice constants of these phases increases with the number of cuprate planes (see table below). The coordination of the Cu atom is different in the three phases. The Cu atom forms an octahedral coordination with respect to oxygen atoms in the 2201 phase, whereas in 2212, the Cu atom is surrounded by five oxygen atoms in a pyramidal arrangement. In the 2223 structure, Cu has two coordinations with respect to oxygen: one Cu atom is bonded with four oxygen atoms in square planar configuration and another Cu atom is coordinated with five oxygen atoms in a pyramidal arrangement.
To treat the condition, high concentration doses of glucose are given to the neonate as required maintaining normal blood glucose levels. The hyperinsulinemia condition subsides after one to two days.
This is an important consideration because cholesterol—the precursor to all steroid hormones—does not leave the membrane once it has embedded itself inside. The difference between cholesterol and these hormones is that cholesterol is in a much larger negative Gibb's free energy well once inside the membrane, as compared to these hormones. This is because the aliphatic tail on cholesterol has a very favorable interaction with the interior of lipid bilayers.
Sources: en.wikipedia.org
Nuclear emulsions are similar to photographic emulsions, except that they are used in particle physics to detect high-energy elementary particles. Whilst an emulsion roughly corresponds to a mixture of at least two immiscible liquids mixed together, by contrast emulsification is the process of dispersing two or more immiscible liquids together through the use of an emulsifier (e.g., lecithin in a mixture of oil and water). Nanoemulsification is the process of emulsification in the nanoscale. A nanoemulsion is a particular kind of emulsion, with droplet sizes on the order of 100 nm.
== Acidity == The tropylium ion is an acid in aqueous solution (i.e., an Arrhenius acid) as a consequence of its Lewis acidity: it first acts as a Lewis acid to form an adduct with water, which can then donate a proton to another molecule of water, therefore indirectly acting as an Arrhenius acid:
Ritonavir is sold as Norvir by AbbVie, Inc. The US Food and Drug Administration (FDA) approved ritonavir on March 1, 1996, As a result of the introduction of "highly active antiretroviral thearap[ies]" the annual U.S. HIV-associated death rate fell from over 50,000 to about 18,000 over a period of two years. In 2014, the FDA approved a combination of ombitasvir/paritaprevir/ritonavir for the treatment of hepatitis C virus (HCV) genotype 4. After the start of the COVID pandemic in 2020, many antivirals, including protease inhibitors in general and ritonavir in particular, were repurposed in an effort to treat the new infection. Lopinavir/ritonavir was found not to work in severe COVID-19. Virtual screening followed by molecular dynamics analysis predicted ritonavir blocks the binding of the SARS-CoV-2 spike (S) protein to the human angiotensin-converting enzyme 2 (hACE2) receptor, which is critical for the virus entry into human cells. Finally in 2021, a combination of ritonavir with nirmatrelvir, a newly developed orally active 3C-like protease inhibitor, was developed for the treatment of COVID-19. Ritonavir serves to slow down metabolism of nirmatrelvir by cytochrome enzymes to maintain higher circulating concentrations of the main drug. In November that year, Pfizer announced positive phase 2/3 results, including 89% reduction in hospitalizations when given within three days after symptom onset.
== Titanium-44 == Titanium-44 (44Ti) is a radioactive isotope of titanium that undergoes electron capture with a half-life of 59.1 years to an excited state of scandium-44, before reaching the ground state of 44Sc and ultimately of 44Ca. Because titanium-44 can decay only through electron capture, its half-life increases slowly with its ionization state and it becomes stable in its fully ionized state (that is, having a charge of +22), though as astrophysical environments never lack electrons completely, it will always decay. Titanium-44 is produced in relative abundance in the alpha process in stellar nucleosynthesis and the early stages of supernova explosions. It is produced when stable calcium-40 adds an alpha particle (helium-4), as nickel-56 is the result of adding three more. The age of supernova remnants (even though nickel-56 has died away to iron) may be determined through measurements of gamma-ray emissions from the relatively long-lived titanium-44 and of its abundance. It was observed in the Cassiopeia A supernova remnant and SN 1987A at a relatively high concentration, enhanced by the delayed decay in the ionizing conditions.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.
Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.
Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.